ASCO-GI – confirmation for Bristol’s combo, but is there more?
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
ASCO-GI – some shine comes off Astra’s Emerald
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
ASCO-GI – another surprising TIGIT success?
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.
Car-T comes full circle
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
Merck KGaA’s oncology catalyst approaches
Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.
